« Return to News | Clinical Intelligence

AstraZeneca drug enters phase III

Friday, March 18, 2011 10:28 AM

AstraZeneca has begun enrollment of a late-stage trial for an investigational opioid-induced constipation treatment licensed from Nektar Therapeutics.

The drug, NKTR-118, is a once-daily tablet that combines Nektar's small molecule polymer conjugate technology platform with naloxol, a derivative of the opioid antagonist naloxone. It is being studied for OIC, a common side effect of prescription opioids used for chronic pain management.

AZ said for those patients who take opiates for long-term pain management, 40% to 50% will develop constipation. Only half of those experience effective relief from laxatives and stool softeners.

The first regulatory filings based on the program are planned for 2013. AstraZeneca and Nektar teamed up in September 2009; the deal includes the earlier-stage NKTR-119, which combines NKTR-118 and an opioid analgesic. When the pact was signed, AstraZeneca made a $125 million upfront payment. The deal could be worth $1.5 billion to Nektar.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.